The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations. In accordance with the Inflation Reduction Act, the negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027. Between November 2023 and October 2024, about 5.3 million people with Medicare Part D coverage used these drugs to treat a variety of conditions, such as cancer, type 2 diabetes, and asthma. These selected drugs accounted for about $41 billion in total gross covered prescription drug costs under Medicare Part D, or about 14%, during that period. When combined with the total gross covered prescription drug costs under Medicare Part D of the 10 drugs selected for the first cycle of negotiations over that same time, this represents over a third of total gross covered prescription drug costs under Medicare Part D. You can read more about the announcement and selected drugs in this HHS Press Release and CMS Factsheet.

President Trump ordered all executive departments and agencies to take the following steps:

·    Do not propose or issue any rule in any manner, including by sending a rule to the Office of the Federal Register (the OFR), until a department or agency head appointed or designated by the President after noon on Jan. 20, 2025, reviews and approves the rule.

·    Immediately withdraw any rules that have been sent to the OFR but not published in the Federal Register

·    Consistent with applicable law and subject to the exceptions described in paragraph one, consider postponing for 60 days from the date of the memorandum the effective date for any rules that have been published in the Federal Register.

President Trump signed an Executive Order that terminates DEI preferencing in federal contracting and directs federal agencies to combat private sector discrimination. The enforces long-standing federal statutes and faithfully advances the Constitution’s promise of colorblind equality before the law. Read the fact sheet.

Congress faces an array of policy choices as it confronts large federal deficits and rising federal debt. In June 2024, under the assumption that current laws governing taxes and spending generally would not change, the Congressional Budget Office (CBO) projected that the federal deficit would average $1.9 trillion per year between 2025 and 2034, or 5.4 percent of gross domestic product (GDP) over that period. In comparison, over the past 50 years, the annual deficit averaged 3.7 percent of GDP. In response, the CBO published Options for Reducing the Deficit: 2025 to 2034 in December 2024.

Novartis this week became the fifth manufacturer to sue the Health Resources and Services Administration (HRSA) to implement a 340B rebate model. Novartis filed its complaint Wednesday in the US District Court for the District of Columbia.

Reps. Vern Buchanan (FL) and David Schweikert (AZ) will continue to chair the Ways & Means health and oversight subcommittees, respectively. Buchanan brings with him expertise on CMS coverage issues and a pledge to push the incoming administration’s goals to cut regulations and offer alternative coverage options. Schweikert advocates for telehealth and artificial intelligence.

The Pennsylvania State Data Center (PaSDC) invites presenters to participate in the 2025 Pennsylvania Data User Conference. This year’s event will be held on May 15, 2025, at Penn State Harrisburg in Middletown. The annual Data User Conference serves as Pennsylvania’s most comprehensive single-day forum for research and developments in demographic and socioeconomic data.

The PaSDC Data User Conference aims to educate its audience on demographic and socioeconomic research and policies affecting Pennsylvania. Past presentations have focused on research themes (e.g., aging, prison populations, labor force, and rural Pennsylvania), community development (e.g., case studies and community planning), innovations in technology (e.g., database and data visualization software), and other data-related topics.

Sessions at the conference are non-commercial and vendor neutral. Under no circumstance should a session be a direct promotion of an organization’s product, service, or monetary self-interest. The emphasis should be on the application of demographic and socioeconomic data, technology, and other timely topics.

Submission Details

Proposals will be accepted for team, individual, or panel presentations. To propose a session, please email the topic and a brief description or outline (maximum 250 words) to Jennifer Shultz (jjb131@psu.edu) by Wednesday, February 26, 2025. The PaSDC will notify all selected speakers by March 7, 2025.

Presentation Rules

Presentation proposals will be reviewed by the conference planning committee and selections will be made based upon desired topics, flow, educational value, and understanding of the content. All selected presentations will be published in conference material and online.

Agenda Schedule

All presentations will be on May 15, 2025. Conference organizers will set the time for each presentation to optimize the sequencing and flow of content and tracks. Sessions will end by 5:00 PM.

Speaker Benefits

The PaSDC does not pay fees or travel expenses for speakers. All speakers receive complimentary conference registration, including meals, and are featured in the conference publication and on the conference website. These benefits apply only to speaker(s) and do not extend to support staff or colleagues who may accompany them.